FRI0464 Clinical manifestations of persistent antiphospholipid antibodies in systemic sclerosis patients. (12th June 2018) - Myriam, S.
Abstract : Background: Antiphospholipid antibodies (aPL) can be detected in systemic sclerosis (SSc) patients. While their clinical signification is well known in the primary antiphospholipid syndrome (APS), their frequency and clinical association remain debated matter of issue. In a previous study, we reported the prevalence and their clinical association of a single aPL testing a French cohort of SSc patients. Yet, the persistence of aPL during follow-up of patients has never been assessed. Objectives: This study aimed to assess i. the persistence of aPL at least 12 weeks after the first dosage and ii. the clinical associations. Methods: At least 12 weeks apart after the first test, 213 SSc patients were consecutively tested for lupus anticoagulant (LA), anticardiolipin (aCL) and anti-ß2glycoproteine 1 (anti-ß2Gp1) antibodies. aCL and anti-β2GpI were measured using commercial ELISA assays (Orgentec, Trappes, France), positivity was defined as ≥10 UGPL/mL (aCL) or ≥10 UA/mL (anti-β2GpI). Clinical associations were studied using binomial logistic regressions. Results: The mean time between two tests was 13.2±6.3 months. One or more type of aPL was persistent in 7 patients (3%). Patients with persistent aPL developed more frequently venous thrombosis (VT) [4/7 (57%) versus 23/205 (11%), p=0.006]. Arterial or/and venous thrombosis were more common in patients with persistent aPL than other patients [4/7 (57%) versus 33/205 (16%), p<0.001]. Persistent aPL was also associated with miscarriages [4/6 (67%) versus 33/155 (21%), p=0.023]. Conclusions: The prevalence of persistent aPL in our cohort was 3%. VT and miscarriages were associated with persistent aPL. References: [1] Parodi A, Drosera M, Barbieri L, Rebora A. Antiphospholipid antibody system in systemic sclerosis. Rheumatology (Oxford)2001;40:111–12. [2] Sanna G, Bertolaccini ML, Mamali A, et al. Antiphospholipid anti- bodies in patients with scleroderma: prevalence and clinical signifi- cance. Ann Rheum Dis2005. [3] Marie I, et al. Anticardiolipin, ab2GPI antibodies and lupus-like anticoagulant in SSc. [4] Miryakis S, Lockshin MD, Atsumi T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006;4:295. Disclosure of Interest: None declared